Subscribe
Previous Post
The FDA has just approved the fast acting insulin Apidra to be used in a clinical setting in an inraveneous route. This is good news for both type 1 and type 2 diabetics that are hospitalized and are in need for glycemic control.
Apidra is a rapid-acting insulin that offers patients mealtime dosing flexibility-it can be taken within 15 minutes before or within 20 minutes after starting a meal. Apidra is also flexible for use in diabetes patients with diverse body types from lean to obese. Nearly 9 out of 10 people with newly diagnosed type 2 diabetes are overweight, and for patients that require insulin therapy, this presents an additional challenge, as being overweight can affect the speed at which insulin is absorbed by the body. In clinical studies, Apidra was found to maintain its rapid onset of action and absorption when it was given to subjects with lean to obese body types
Well hot dog! Apidra seems quite the chameleon. Not one person’s diabetes is the same nor calls for the same treatment. This injectable insulin is great in that you can use it before or after you have already started your meal. That gives clinicians a much better window of success over the management of your diabetes. And for absorption purposes, it seems that an IV route allows you to leap right over that hurdle.
I look forward to using this in a clinical setting. Who knows, the next patient that I treat might be you. And hears to successful management of type 1 and type 2 diabetes!
via PR Newswire
I will have to look into statistics and get back to you! I haven’t used it yet in clinical practice personally, but I will check into it. Thanks for the question!
What’s so magic about this insulin that it can be taken after the start of a meal. In theory Humalog can be taken immediately before eating. But it works much better when taken about 10-15 minutes before food.
Is Apidra’s behavior that different to Humalog? It also seems to be targeted to type 2 diabetes. Do you know whether many folks with type 1 are using it?